Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0ZEDFH |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | M2 |
|||||
| Organization | EXELIXIS, INC. |
|||||
| Synonyms |
M2
Click to Show/Hide
|
|||||
| Antibody Type | Bispecific antibody (BsAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1); Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYFIHWVRQAPGKGLEWVAGIYPSEGYTSY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYYVSGMDYWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLOSSGLY SLSSVVTVPSSSLGTOTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Light Chain Sequence |
EVGSYHDHHFDCYYFDPPSHCPAGGGPLGLAGSGGSDIQMTQSPSSLSASVGDRVTITCR
ASQSVSSAVAWYQQKPGKAPKLLIYSASSLQSGVPSRFSGSRSGTDFTLTISSLQPEDFA TYYCQQYYYYPGTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA KVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP VTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
EVGSYHDHHFDCYYFDPPSHCPAGGGPLGLAGSGGSDIQMTQSPSSLSASVGDRVTITCR
ASQSVSSAVAWYQQKPGKAPKLLIYSASSLQSGVPSRFSGSRSGTDFTLTISSLQPEDFA TYYCQQYYYYPGTFGQGTKVEIK Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
wO2025019776A2ADC-13 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
CB.17 female SCID mice were inoculated subcutaneously in the right up flank region with Jeko-1 tumor cells (5×10 6)in 0.1 mL of PBS with Matrigel (1:1)for tumor development.When the tumor volumes reached about 150~250 mm 3on Day 1,mice were randomized into respective treatment groups (8 mice per group).The mice then received intravenous injections of vehicle or the tested ADC-13 at 7.5mg/kg on Day 1 and Day 8.PBS vehicle was tested in parallel,serving as a control.
Click to Show/Hide
|
||||
| In Vivo Model | JEKO-1 MCL Xenograft Model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 60% | Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
CB.17 female SCID mice were implanted (flank)with 1.0x10 7of MDA-MB-231 tumor cells in 50%MATRIGELR (Corning Life Sciences)matrix (1:1 cell to Matrigel) on Day -13.When the average tumor volume reached about 200 mm 3on Day 1,mice were randomized into respective treatment groups (10 mice per group).The mice then received intravenous injections of the tested ADC-13 at 7.5 mg/kg on Day 1 and Day 8.PBS vehicle was tested in parallel,serving as a control.Body weight and tumor volume were measured twice per week.The study was ended on Day 45.
Click to Show/Hide
|
||||
| In Vivo Model | MDA-MB-231 TNBC Xenograft Model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.1-1 nM
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
In vitro cytotoxicity of the ADC-00 was assessed on hROR1 expressing HEK cells with a top concentration of 10 nM, and ADC-00 was serially diluted 1:4, The treated cells were incubated for 5 days.The cell viability reading was taken. In order to activate the masked ADCs,an enzyme digestion system MMP9 was added.
|
||||
| In Vitro Model | Endocervical adenocarcinoma | HEK cells | CVCL_M624 | ||
References